diclofenac has been researched along with Liver Diseases in 19 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study investigated: (1) the effects of mild or moderate renal insufficiency and mild hepatic impairment on the pharmacokinetics (PK) of diclofenac and hydroxypropyl-β-cyclodextrin (HPβCD) following administration of the injectable NSAID HPβCD-diclofenac; and (2) the PK of HPβCD following administration of HPβCD-diclofenac and intravenous itraconazole formulated with HPβCD in healthy adults." | 9.27 | Pharmacokinetics of Diclofenac and Hydroxypropyl-β-Cyclodextrin (HPβCD) Following Administration of Injectable HPβCD-Diclofenac in Subjects With Mild to Moderate Renal Insufficiency or Mild Hepatic Impairment. ( Carr, DB; Ernst, CC; Hamilton, DA; Kramer, WG; Lacouture, PG; Lang, E; Liao, E; Madden, D; Ramaiya, A, 2018) |
| "Ten patients with chronic hepatitis or cirrhotic hepatitis without portal decompensation diagnosed by biochemical, laparoscopical and histological criteria were given 100 mg diclofenac-Na (Voltaren) p." | 7.66 | [Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease]. ( Degen, P; Tittor, W; Zimmerer, J, 1982) |
| " This study investigated: (1) the effects of mild or moderate renal insufficiency and mild hepatic impairment on the pharmacokinetics (PK) of diclofenac and hydroxypropyl-β-cyclodextrin (HPβCD) following administration of the injectable NSAID HPβCD-diclofenac; and (2) the PK of HPβCD following administration of HPβCD-diclofenac and intravenous itraconazole formulated with HPβCD in healthy adults." | 5.27 | Pharmacokinetics of Diclofenac and Hydroxypropyl-β-Cyclodextrin (HPβCD) Following Administration of Injectable HPβCD-Diclofenac in Subjects With Mild to Moderate Renal Insufficiency or Mild Hepatic Impairment. ( Carr, DB; Ernst, CC; Hamilton, DA; Kramer, WG; Lacouture, PG; Lang, E; Liao, E; Madden, D; Ramaiya, A, 2018) |
| "Patients > or = 50 years with rheumatoid arthritis or osteoarthritis were randomly assigned to diclofenac (150 mg daily) or etoricoxib (60 or 90 mg daily)." | 5.14 | How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. ( Cannon, CP; Connors, LG; Curtis, SP; Goldkind, L; Laine, L; Yanqiong, Z, 2009) |
| "Ten patients with chronic hepatitis or cirrhotic hepatitis without portal decompensation diagnosed by biochemical, laparoscopical and histological criteria were given 100 mg diclofenac-Na (Voltaren) p." | 3.66 | [Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease]. ( Degen, P; Tittor, W; Zimmerer, J, 1982) |
| " Lumiracoxib has good oral bioavailability (74%)." | 2.43 | Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ( Choi, L; Mangold, JB; Marshall, P; Rordorf, CM, 2005) |
| "However, some patients may develop acute liver failure and successful orthotopic liver transplantation may be undertaken in such patients." | 2.42 | Hepatocellular damage from non-steroidal anti-inflammatory drugs. ( Dargan, PI; Jones, AL; O'Connor, N, 2003) |
| "The knowledge of pharmacokinetic and pharmacodynamic properties of antiepileptic drugs is helpful in optimizing drug therapy for epilepsy." | 1.46 | Evaluation of Brain Pharmacokinetic and Neuropharmacodynamic Attributes of an Antiepileptic Drug, Lacosamide, in Hepatic and Renal Impairment: Preclinical Evidence. ( Kumar, B; Medhi, B; Modi, M; Saikia, B, 2017) |
| " Despite the many available forms of NSAIDs, including injectable as well as topical, oral dosing is the most common route, usually the one route consistently associated with chronic use and thus the one that carries the most risk." | 1.39 | Nonsteroidal anti-inflammatory drugs and their risk: a story still in development. ( Simon, LS, 2013) |
| "Diclofenac sodium was used as the toxicant in hepatoprotective studies, in which various serum biochemical parameters and liver glycogen were assessed." | 1.35 | Assessment of anti-inflammatory and hepatoprotective potency of Polyalthia longifolia var. pendula leaf in Wistar albino rats. ( Chanda, S; Nair, R; Tanna, A, 2009) |
| " An analysis of variance was used to detect differences in PK parameters (AUC, Cmax and Tmax) between the treatment groups." | 1.32 | No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. ( Kalbag, J; Lasseter, K; Milosavljev, S; Oberstein, S; Rordorf, C; Yeh, CM, 2004) |
| "Diclofenac is a nonsteroidal anti-inflammatory drug approved in the United States in 1988 for the treatment of patients with osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis." | 1.29 | Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. ( Banks, AT; Harter, JG; Ishak, KG; Zimmerman, HJ, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, B | 1 |
| Modi, M | 1 |
| Saikia, B | 1 |
| Medhi, B | 1 |
| Hamilton, DA | 1 |
| Ernst, CC | 1 |
| Kramer, WG | 1 |
| Madden, D | 1 |
| Lang, E | 1 |
| Liao, E | 1 |
| Lacouture, PG | 1 |
| Ramaiya, A | 1 |
| Carr, DB | 1 |
| Simon, LS | 1 |
| Tanna, A | 1 |
| Nair, R | 1 |
| Chanda, S | 1 |
| Laine, L | 1 |
| Goldkind, L | 1 |
| Curtis, SP | 1 |
| Connors, LG | 1 |
| Yanqiong, Z | 1 |
| Cannon, CP | 1 |
| Davern, TJ | 1 |
| Chalasani, N | 1 |
| O'Connor, N | 1 |
| Dargan, PI | 1 |
| Jones, AL | 1 |
| Kalbag, J | 1 |
| Yeh, CM | 1 |
| Milosavljev, S | 1 |
| Lasseter, K | 1 |
| Oberstein, S | 1 |
| Rordorf, C | 1 |
| Snyman, T | 1 |
| Stewart, MJ | 1 |
| Grove, A | 1 |
| Steenkamp, V | 1 |
| Rordorf, CM | 1 |
| Choi, L | 1 |
| Marshall, P | 1 |
| Mangold, JB | 1 |
| Zimmerer, J | 1 |
| Tittor, W | 1 |
| Degen, P | 1 |
| Banks, AT | 1 |
| Zimmerman, HJ | 1 |
| Ishak, KG | 1 |
| Harter, JG | 1 |
| Takayama, F | 1 |
| Egashira, T | 1 |
| Yamanaka, Y | 1 |
| Manoukian, AV | 1 |
| Carson, JL | 1 |
| Farrell, GC | 1 |
| Tolman, KG | 1 |
| Novacek, G | 1 |
| Geppert, A | 1 |
| Kramer, L | 1 |
| Wrba, F | 1 |
| Herbst, F | 1 |
| Schima, W | 1 |
| Gangl, A | 1 |
| Pötzi, R | 1 |
| Wouters, JM | 1 |
| van Rijswijk, MH | 1 |
| van de Putte, LB | 1 |
| Roth, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of DIC075V in Subjects With Mild or Moderate Chronic Renal Insufficiency and in Subjects With Mild Chronic Hepatic Impairment Compared to Healthy Adult Volunteers and a Randomize[NCT00805090] | Phase 1 | 37 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| The Effect of Chronic Pain Relief Over Knee Joint Area by Gua Sha Therapy[NCT03821194] | 40 participants (Anticipated) | Interventional | 2019-01-25 | Recruiting | |||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703] | Phase 3 | 6,000 participants | Interventional | 2002-06-27 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis[NCT00092742] | Phase 3 | 4,086 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for diclofenac and Liver Diseases
| Article | Year |
|---|---|
Drug-induced liver injury in clinical trials: as rare as hens' teeth.
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Diclofenac; Drug-Related Side Effe | 2009 |
Hepatocellular damage from non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemical and Drug Induced Liver Injury; D | 2003 |
Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Ki | 2005 |
Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chemical and Drug Induced Liver Injur | 1996 |
Drug-induced hepatic injury.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Aza | 1997 |
Hepatotoxicity of non-narcotic analgesics.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Inj | 1998 |
Liver penetration by a duodenal ulcer in a young woman.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Diclofenac; | 2001 |
2 trials available for diclofenac and Liver Diseases
| Article | Year |
|---|---|
Pharmacokinetics of Diclofenac and Hydroxypropyl-β-Cyclodextrin (HPβCD) Following Administration of Injectable HPβCD-Diclofenac in Subjects With Mild to Moderate Renal Insufficiency or Mild Hepatic Impairment.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; | 2018 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
10 other studies available for diclofenac and Liver Diseases
| Article | Year |
|---|---|
Evaluation of Brain Pharmacokinetic and Neuropharmacodynamic Attributes of an Antiepileptic Drug, Lacosamide, in Hepatic and Renal Impairment: Preclinical Evidence.
Topics: Acetamides; Administration, Oral; Animals; Anticonvulsants; Area Under Curve; Brain; Carbon Tetrachl | 2017 |
Nonsteroidal anti-inflammatory drugs and their risk: a story still in development.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Rheumatoid; Cardiovascular Diseases; | 2013 |
Assessment of anti-inflammatory and hepatoprotective potency of Polyalthia longifolia var. pendula leaf in Wistar albino rats.
Topics: Acetone; Alanine Transaminase; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Chemi | 2009 |
No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor.
Topics: Administration, Oral; Area Under Curve; Bilirubin; Case-Control Studies; Cyclooxygenase Inhibitors; | 2004 |
Adulteration of South African traditional herbal remedies.
Topics: Acidosis, Lactic; Adult; Chemical and Drug Induced Liver Injury; Child, Preschool; Chromatography, H | 2005 |
[Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease].
Topics: Adult; Chemical Phenomena; Chemistry; Diclofenac; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases | 1982 |
Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Diclofenac; | 1995 |
Effect of diclofenac, a non-steroidal anti-inflammatory drug, on lipid peroxidation caused by ischemia-reperfusion in rat liver.
Topics: Animals; Diclofenac; Free Radical Scavengers; Lipid Peroxidation; Liver; Liver Diseases; Male; Micro | 1994 |
Adult onset Still's disease in the elderly: a report of two cases.
Topics: Aged; Arthritis; Arthritis, Juvenile; Chemical and Drug Induced Liver Injury; Diagnosis, Differentia | 1985 |
Special studies of diclofenac and safety: gastrointestinal, renal, hepatic, and other consequences of therapy.
Topics: Age Factors; Diclofenac; Endoscopy; Gastrointestinal Diseases; Humans; Kidney Diseases; Kinetics; Li | 1985 |